The Michael J. Fox Foundation (MJFF) has awarded a $14.7 million research grant to Verily, an artificial intelligence platform for health analytics, to generate a detailed set of molecular information for Parkinson’s disease research. Verily will analyze biological samples, including blood and cerebrospinal fluid, from participants in the…
The Michael J. Fox Foundation (MJFF) is expanding its Parkinson’s Progression Markers Initiative (PPMI) to provide free Parkinson’s disease risk screening to people 40 years and older. The move will allow PPMI to screen more people using blood testing and tests of smell loss, a possible early…
Defects in VPS13C, a protein whose dysfunction has been linked to Parkinson’s disease, can prevent cells from repairing damage to their waste disposal systems, a study shows. VPS13C and other proteins associated with genetic forms of Parkinson’s help repair damaged lysosomes, which are cell components that recycle waste. Without…
A group of U.S. veterans with Parkinson’s disease has added a novel tool to their therapeutic regimen: building with Legos. For about a year, the group, based out of the Central Virginia Veterans Affairs (VA) Health Care System, has been building Lego creations to exercise their motor skills and…
The Healthwell Foundation — a U.S. nonprofit seeking to improve healthcare access for underinsured patients — has launched a fund to help Medicare beneficiaries with Parkinson’s disease cover the costs of treatment. Eligible individuals undergoing treatment for Parkinson’s in the U.S. can apply online for a…
A new open-source software called VisionMD may help doctors assess motor symptoms of Parkinson’s disease and other movement disorders with artificial intelligence (AI)-enabled video analysis, a study reports. Analyzing videos of patients tapping their fingers and doing other clinical tests can help clinicians understand disease progress and…
Researchers and students at the University of Wisconsin-La Crosse (UWL) are developing evidence-based occupational therapy practices to help people with Parkinson’s disease manage their condition and regain the ability to participate in the activities they enjoy. The research aims to help occupational therapy professionals deliver the best possible…
Photopharmics will use $6 million in newly secured funding to complete a Phase 3 clinical trial testing Celeste, its light therapy device for Parkinson’s disease, and to support precommercialization efforts before submitting regulatory applications. The ongoing Phase 3 trial (NCT04453033), dubbed Light for PD, has enrolled more…
The Parkinson Voice Project (PVP) has awarded a specialized training grant to the speech-language pathology program at Yeshiva University in New York that will enable graduate students to offer virtual SPEAK OUT! voice therapy to people living with Parkinson’s disease. SPEAK OUT! is a research-backed therapy program…
1ST Biotherapeutics said it joined an initiative led by the Michael J. Fox Foundation (MJFF) aimed at advancing therapies that target the LRRK2 gene, a key genetic contributor to Parkinson’s disease. The initiative, MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, brings together biotech companies and academic research…
Get regular updates to your inbox.
